nOPV2

To better address the evolving risk of type 2 variant poliovirus (cVDPV2), GPEI partners together with countries have developed and deployed an innovative tool – the novel oral polio vaccine type 2 (nOPV2). The vaccine is a next-generation version of the type 2 monovalent OPV (mOPV2), which clinical trials and field use have shown is as safe to use and provides comparable protection against poliovirus while being much more genetically stable and therefore less likely to be associated with new cVDPV2 outbreaks.  

Development of nOPV2 began in 2011, and in March 2021, it was rolled out for outbreak response after it was granted WHO Emergency Use Listing (EUL) approval to enable its rapid field availability. As of December 2023, approximately 1 billion doses of the vaccine have been administered across 35 countries, providing protection to millions of children against illness and debilitating paralysis.  

 In December 2023, nOPV2 earned full licensure from Indonesian regulatory authority (Badan POM) as well as WHO Prequalification (PQ) after rigorous reviews of safety, effectiveness and genetic stability data, as well as quality assurance checks of manufacturing sites. This marked the end of its EUL use phase, making it easier for more countries to access and use nOPV2 for outbreak response.  

nOPV2 is the first EUL-approved vaccine to achieve prequalification. The vaccine will continue to be an important tool to help stop variant poliovirus outbreaks more sustainably. 

Key Resources

GPEI nOPV2-cVDPV2 fact sheet | English | French |

nOPV2 Frequently Asked Questions (FAQs) | English | French | Arabic |

nOPV2 technical brief | English | French | Russian | Portuguese |

PATH fact sheet: Advancing novel polio vaccines | English |

nOPV2 animation video | English | French | Portuguese | Spanish | Arabic | Somali | Urdu | Pashto | Dari | Farsi |

WHO Emergency Use Listing procedure infographic | English | French |

Clinical summary for novel oral polio vaccine type 2 (nOPV2) |EnglishFrench | Arabic | Portuguese | Russian | Spanish |

Scientific publications on nOPV2:

WHO PQ Assessment Report on nOPV2 | English | French |

Polio Vaccine – Novel Oral (nOPV) Monovalent type 2 | English |

Preparing for nOPV2 Use: An overview on requirements for countries | English | French | Russian | Portuguese | Spanish |

Technical brief | English | French | Russian | Portuguese |

nOPV2 Readiness Verification and Dose Release Process | English | French | Russian | Portuguese |

nOPV2 Vaccine Management Guidance | English | French | Russian | Portuguese | Spanish |

nOPV2 Vaccine Handling | English | French | Russian | Portuguese |

nOPV2 Surveillance Guidance | English | French | Russian | Portuguese |

nOPV2 Safety Guidance | English | French | Russian | Portuguese |

nOPV2 AESI guidance | English | French | Russian | Portuguese |

GPEI polio outbreak response training | English |

Introduction of nOPV2 for Polio Outbreak Response: Supervisory manual | English | French |

Novel oral polio vaccine type 2 (nOPV2) Vaccine-Related Event (VRE) Response Plan | English | French | Arabic | Portuguese |

VRE development guidance note for countries | English | French | Portuguese |

UNICEF Strategic C4D Communications Guidance for Outbreak Response including nOPV2 | English |

Programme Advocacy package for cVDPV Outbreak Response and nOPV2 Introduction | English |

Vaccine Misinformation Management Field Guide | English |

SAGE Recommendations – March 2023 Meeting (Weekly Epidemiological Record) – English and French

SAGE Recommendations – October 2022 Meeting (Weekly Epidemiological Record) – English and French

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 4-7 October 2021 |English |

SAGE Recommendations – October 2021 Meeting (Weekly Epidemiological Record) – English and French

SAGE Recommendations – June 2021 Meeting (Weekly Epidemiological Record) – English and French

SAGE Recommendations – October 2020 Meeting (Weekly Epidemiological Record) – English and French

SAGE Recommendations April 2020 Meeting (Weekly epidemiological record) – English and French

WHO Executive Board decision urging Member States to expedite processes for authorizing the importation and use of nOPV2 on the basis of its emergency use listing – February 2020 | English| French|

SAGE Recommendations, October 2019 Meeting (Weekly epidemiological record) – English and French

Media center

Additional Resources and Updates